Skip to content

AARD AARD Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$47.16M

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's net proceeds from sales of subsidiary shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's net proceeds from sales of subsidiary shares?
AARD (AARD) reported net proceeds from sales of subsidiary shares of $0 in Q1 2026.
How has AARD's net proceeds from sales of subsidiary shares changed year-over-year?
AARD's net proceeds from sales of subsidiary shares decreased by 100.0% year-over-year, from $91.08M to $0.
What does net proceeds from sales of subsidiary shares mean?
Captures the total cash proceeds received by the company from the issuance of equity securities during its initial public offering. This metric indicates the primary capital infusion generated from entering public markets to fund ongoing operations and research.